Payment overview · 2025
General Payments
$373.45
21 reported records · 10 companies
Healthcare provider profile · identity verified
Douglas Frederick Johnston, DO
Allopathic & Osteopathic Physicians|Family Medicine · TYLER, TX · NPI 1083641559
Verified facts
What the public records show
CMS Open Payments records show Douglas Frederick Johnston, DO received $373.45 in general payments during 2025 across 21 reported records.
Exact Sciences Corporation accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Mounjaro by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.22 | 23.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.04 | 21.2% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $69.90 | 18.7% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $39.85 | 10.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.92 | 6.1% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.60 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.44 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.10 | 3.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $13.05 | 3.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.33 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.45 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.04 | 5 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $69.90 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $54.73 | 3 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $13.05 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
191 | 26 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 84 |
| Losartan Potassium | Losartan Potassium | 244 | 70 |
| Gabapentin | Gabapentin | 213 | 66 |
| Metformin Hcl | Metformin Hcl | 209 | 60 |
| Lisinopril | Lisinopril | 204 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 64 |
| Simvastatin | Simvastatin | 194 | 52 |
| Mounjaro | Tirzepatide | 191 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 171 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Omeprazole | Omeprazole | 151 | 45 |
| Furosemide | Furosemide | 139 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 45 |
| Sertraline Hcl | Sertraline Hcl | 131 | 37 |
| Allopurinol | Allopurinol | 129 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 41 |
| Tramadol Hcl | Tramadol Hcl | 114 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 35 |
| Ozempic | Semaglutide | 111 | 15 |
| Eliquis | Apixaban | 99 | 18 |
| Trazodone Hcl | Trazodone Hcl | 99 | 23 |
| Bupropion Xl | Bupropion Hcl | 92 | 29 |
| Potassium Chloride | Potassium Chloride | 92 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 25 |
| Alprazolam | Alprazolam | 90 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 29 |
| Carvedilol | Carvedilol | 89 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 12 |
| Alendronate Sodium | Alendronate Sodium | 77 | 25 |
| Meloxicam | Meloxicam | 75 | 26 |
| Montelukast Sodium | Montelukast Sodium | 75 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 21 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 19 |
| Spironolactone | Spironolactone | 54 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 19 |
| Temazepam | Temazepam | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 27 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Glimepiride | Glimepiride | 40 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | 12 |
| Atenolol | Atenolol | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Prednisone | Prednisone | 27 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Famotidine | Famotidine | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.45 · 21 records | Exact Sciences Corporation | AMPLATZER AMULET, Azstarys, Cologuard Collection Kit, DAYBUE, Dyanavel XR, Heplisav-B, Kerendia, MOUNJARO, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error